Subclinical Epstein-Barr virus Viremia among adult renal transplant recipients: Incidence and consequences

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 656-662

  Bamoulid, J ^a,b,c   Courivaud, C ^a,b,c   Coaquette, A ^c   Chalopin, J M ^a,b,c,d   Gaiffe, E ^c,d   Saas, P ^a,b,c,d   Ducloux, D ^a,b,c  

^a CNRS   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Epstein Barr virus; kidney transplantation

Indexed keywords

COTRIMOXAZOLE; CREATININE; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; BACTERIAL INFECTION; BK VIRUS INFECTION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ATROPHY; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; VIREMIA;

EID: 84874404369     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12009     Document Type: Review

References (18)

1. Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002; 2: 946-954.
2. Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Baumgardner GL,. Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients. Am J Transplant 2011; 11: 1058-1063.
3. Holmes MV, Caplin B, Atkinson C, et al. Prospective monitoring of Epstein-Barr virus in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. Transplantation 2009; 87: 852-856.
4. Tanaka E, Sato T, Ishihara M, et al. Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients. Pediatr Transplant 2011; 15: 306-313.
5. Kasztelewicz B, Jankowska I, Pawlowska J, et al. Epstein-Barr virus DNA load in peripheral blood mononuclear cells and whole blood from pediatric transplant recipients. Transplant Inf Dis 2011; 13: 471-479.
6. Carbone A, Tirelli U, Gloghini A, Volpe R, Boiocchi M,. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993; 11: 1674-1681.
7. Huggins ML, Todd I, Powell RJ,. Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 2005; 25: 183-187.
8. Taylor AL, Marcus R, Bradley JA,. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155-167.
9. Allen U, Preiksaitis J,. Epstein-Barr virus and post-transplant proliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S87-S96.
10. Lawrence JB, Villnave CA, Singer RH,. Sensitive, high resolution chromatin and chromosome mapping in situ; presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 1989; 52: 51-61.
11. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
12. Nadal D, Guzman J, Frohlich S, Braun DG,. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation. Exp Hematol 1997: 25: 223-231.
13. Van Esser JW, Niesters HG, Van Der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.
14. Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transplant Inf Dis 2009; 11: 393-399.
15. Li L, Chandhuri A, Weintraub LA, et al. Subclinical Cytomegalovirus and Epstein Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11: 187-195.
16. Smith J, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579-1586.
17. Reinke P, Prösch S, Kern F, Volk HD,. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999; 1: 157-164.
18. Lünemann JD, Frey O, Eidner T, et al. Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol 2008; 181: 991-1000.